| Chemical Properties | Back Directory | [density ]
1.38±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
1.01±0.50(Predicted) | [color ]
Light yellow to yellow | [InChI]
InChI=1S/C20H26ClN5OS/c1-5-14(6-2)15-11-12(3)22-19-16(13(4)24-26(15)19)17-18(21)23-20(28-17)25-7-9-27-10-8-25/h11,14H,5-10H2,1-4H3 | [InChIKey]
XVAWSBAQNIXMIO-UHFFFAOYSA-N | [SMILES]
C12=C(C3SC(N4CCOCC4)=NC=3Cl)C(C)=NN1C(C(CC)CC)=CC(C)=N2 |
| Hazard Information | Back Directory | [Uses]
Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia[1]. | [IC 50]
CRFR1 | [storage]
Store at -20°C | [References]
[1] Prete A, et al. Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021;186(1):R1-R14. Published 2021 Nov 30. DOI:10.1530/EJE-21-0794 |
|
|